Usefulness of FDG-PET/CT examination as prediction of effect of immune checkpoint inhibitors in patients with non-small cell lung cancer : a pilot study

Usefulness of FDG-PET/CT examination as prediction of effect of immune checkpoint inhibitors in patients with non-small cell lung cancer : a pilot study - Usefulness of FDG-PET/CT as prediction of effect of immune checkpoint inhibitors in lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031095

Enrollment

Registered

2018-02-02

Start date

2018-02-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced and recurrent non-small cell lung cancer

Interventions

All patients undergo FDG-PET/CT and thallium scintigraphy before and 8 weeks after initiation of immune checkpoint inhibitors therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Aged 20<= 2)Histologically or cytologically proven non-small cell lung cancer 3)Stage IIIB without any indications for radiotherapy or stage IV ECOG PS 0 or 1 4)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients with serious liver dysfunction or renal dysfunction 2)Pregnant or lactating females 3)Patients with clinically significant psychiatric disease that would interfere with participation in this study 4)Patients with history of previous immune checkpoint inhibitor treatment 5)Patients with history of autoimmune diseases 6)Patients with serious interstitial lung disease or infection

Design outcomes

Primary

Measure	Time frame
To evaluate correlation between response rates of immune checkpoint inhibitors by PERCIST, by thallium scintigraphy and by RECIST before and 8 weeks after treatment.	—

Secondary

Measure	Time frame
To evaluate correlation between response rates of immune checkpoint inhibitors by PERCIST, by thallium scintigraphy and progression free survival and overall survival.	—

Countries

Japan

Contacts

Public ContactTakayasu Kurata

Kansai Medecal University Hospital Department of Thoracic Oncology

kuratat@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026